This mechanism is supported by our finding that DR5 receptor internalization occurs more rapidly upon exposure to AmphPVP-BTZ-DR5-B and AmphPVP-BTZ-DR5-B-iRGD rather than to free proteins At the same time, sustained release of the proteasome inhibitor bortezomib (BTZ) from the hydrophobic core can sensitize cancer cells to DR5-mediated apoptosis, creating a powerful, localized combinatorial therapy that minimizes systemic exposure and off-target side toxicity [68]. Here, TNFRSF10B is linked to cancer.